Revolution Medicines, Inc. Sample Contracts
Revolution Medicines, Inc. 13,636,364 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • March 7th, 2023 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
Revolution Medicines, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 13,636,364 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 2,045,454 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
WARRANT AGREEMENT and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated April 6, 2021Warrant Agreement • February 26th, 2024 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
THIS WARRANT AGREEMENT (this “Agreement”), dated April 6, 2021, is by and between CM Life Sciences III Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (in such capacity, the “Warrant Agent”).
LEASE AGREEMENTLease Agreement • October 31st, 2019 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
THIS LEASE AGREEMENT is made as of this 22 day of August, 2012, between ARE-TECH SQUARE, LLC, a Delaware limited liability company (“Landlord”), and WARP DRIVE BIO, LLC, a Delaware limited liability company (“Tenant”).
REVOLUTION MEDICINES, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • February 3rd, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (this “Agreement”) is effective as of _______ by and between Revolution Medicines, Inc., a Delaware corporation (the “Company”), and __________ (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and the Indemnitee covering indemnification.
REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into effective as of December 18, 2019 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Margaret Horn (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of November 9, 2014 (“Offer Letter”).
REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 6th, 2024 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into effective as of August 1, 2024 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Jack Anders (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain Employment Agreement between Executive and the Company dated as of April 29, 2022 (the “Prior Agreement”).
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • February 25th, 2026 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
WHEREAS, capitalized terms used but not defined in this Amendment have the meanings ascribed to them in the Agreement; and
REVOLUTION MEDICINES, INC.Sales Agreement • November 10th, 2021 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
Revolution Medicines, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
AGREEMENT AND PLAN OF MERGER by and among REVOLUTION MEDICINES, INC., TROTSKY MERGER SUB, INC., WARP DRIVE BIO, INC. and FORTIS ADVISORS LLC as the Stockholders’ Representative Dated as of October 15, 2018Merger Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of October 15, 2018, is by and among Revolution Medicines, Inc., a Delaware corporation (“Parent”), Trotsky Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Warp Drive Bio, Inc., a Delaware corporation (the “Company”), and Fortis Advisors LLC, a Delaware limited liability company, in its capacity as the Stockholders’ Representative (“Stockholders’ Representative”).
REVOLUTION MEDICINES, INC. SALES AGREEMENTSales Agreement • February 25th, 2026 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
SUBLEASESublease • October 31st, 2019 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • California
THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of January 16, 2019, and is made by and between ONCOMED PHARMACEUTICALS, INC., a Delaware corporation (“Sublandlord”), and REVOLUTION MEDICINES, INC., a Delaware corporation (“Subtenant”). Sublandlord and Subtenant hereby agree as follows:
REVOLUTION MEDICINES, INC. $500,000,000 SALES AGREEMENTSales Agreement • November 6th, 2024 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
FORM OF COMPANY STOCKHOLDER VOTING AGREEMENTVoting Agreement • August 1st, 2023 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • Delaware
This Voting Agreement (this “Agreement”) is made and entered into as of July 31, 2023 (the “Agreement Date”), by and among Revolution Medicines, Inc., a Delaware corporation (“Parent”), and the undersigned, a stockholder of EQRx, Inc., a Delaware corporation (the “Company”, and such stockholder, the “Stockholder”). Parent and the Stockholder are each individually sometimes referred to herein as a “Party”.
FORM OF STOCKHOLDER LOCK-UP AGREEMENT July 31, 2023Stockholder Lock-Up Agreement • August 1st, 2023 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
SIXTH AMENDMENT TO LEASELease • November 6th, 2024 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
This SIXTH AMENDMENT TO LEASE (“Sixth Amendment”) is made and entered into as of July 12, 2024 (the “Effective Date”), by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), and REVOLUTION MEDICINES, INC., a Delaware corporation (“Tenant”).
COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaborative Research, Development and Commercialization Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
Each Milestone Payment is due only once and will be payable only upon the first Product to achieve the corresponding Milestone Event for the first time.
REVOLUTION MEDICINES, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 5, 2019Investors’ Rights Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of June, 2019, by and among REVOLUTION MEDICINES, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof (collectively, “Investors”), and amends and restates that certain Investors’ Rights Agreement, dated as of March 23, 2018, by and among the Company and the investors listed on Schedule A thereto, as amended (the “Prior Agreement”).
ContractAgreement and Plan of Merger • February 26th, 2024 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • Delaware
Agreement and Plan of Merger, dated as of August 5, 2021, as amended September 21, 2021 and October 28, 2021, by and among CM Life Sciences III, Inc., Clover III Merger Sub, Inc., and EQRx, Inc. (composite copy incorporating the Agreement and Plan of Merger, dated as of August 5, 2021, Amendment to Agreement and Plan of Merger, dated as of September 21, 2021, and Amendment to Agreement and Plan of Merger, dated as of October 28, 2021).
ASSIGNMENT AND ASSUMPTION OF LEASEAssignment and Assumption of Lease • October 31st, 2019 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS ASSIGNMENT AND ASSUMPTION OF LEASE (this “Assignment”) is made by and between WARP DRIVE BIO, LLC, a Delaware limited liability company (“Assignor”) and REVOLUTION MEDICINES, INC., a Delaware corporation (“Assignee”) as of January 30, 2019 (the “Effective Date”).
Revolution Medicines, Inc. $500,000,000 0.50% Convertible Senior Notes due 2033 Underwriting AgreementUnderwriting Agreement • April 17th, 2026 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
THIRD AMENDMENT TO LEASELease • November 10th, 2021 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
This THIRD AMENDMENT TO LEASE ("Third Amendment") is made and entered into as of November 1, 2021 (the “Effective Date”), by and between HCP LS REDWOOD CITY, LLC, a Delaware limited partnership ("Landlord"), and REVOLUTION MEDICINES, INC., a Delaware corporation ("Tenant").
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AGREEMENT dated as of June 23, 2025 among REVOLUTION MEDICINES, INC....Loan Agreement • August 6th, 2025 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
This LOAN AGREEMENT (this “Agreement”), dated as of June 23, 2025 (the “Effective Date”) by and among REVOLUTION MEDICINES, INC., a Delaware corporation (as “Borrower”), WILMINGTON TRUST, NATIONAL ASSOCIATION (as the “Administrative Agent”) and Royalty Pharma Development Funding, LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
REVOLUTION MEDICINES, INC. EARLY EXERCISE STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENTStock Option Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • Delaware
Revolution Medicines, Inc. (the “Company”), pursuant to its 2014 Equity Incentive Plan (the “Plan”), hereby grants to the participant set forth below (“Participant”), an option (the “Option”) to purchase the number of shares of the Company’s Common Stock (referred to herein as “Shares”) set forth below. This Option is subject to all of the terms and conditions as set forth herein and in the Stock Option Agreement attached hereto as Exhibit A (the “Stock Option Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Stock Option Grant Notice and the Stock Option Agreement.
Revolution Medicines, Inc. 10,563,381 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • April 16th, 2026 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
SECOND AMENDMENT TO LEASELease • May 14th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
This SECOND AMENDMENT TO LEASE ("Second Amendment") is made and entered into as of April 17, 2020, by and between HCP LS REDWOOD CITY, LLC, a Delaware limited partnership ("Landlord"), and REVOLUTION MEDICINES, INC., a Delaware corporation ("Tenant").
AGREEMENT AND PLAN OF MERGER among REVOLUTION MEDICINES, INC., a Delaware corporation, EQRX, INC., a Delaware corporation, EQUINOX MERGER SUB I, INC., a Delaware corporation and EQUINOX MERGER SUB II LLC, a Delaware limited liability company Dated as...Merger Agreement • August 1st, 2023 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of July 31, 2023, by and among REVOLUTION MEDICINES, INC., a Delaware corporation (“Parent”), EQRX, INC., a Delaware corporation (the “Company”), EQUINOX MERGER SUB I, INC., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub I”), and EQUINOX MERGER SUB II LLC, a Delaware limited liability company and wholly owned Subsidiary of Parent (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs” and each a “Merger Sub”). Parent, the Company and the Merger Subs are each sometimes referred to herein as a “Party” and, collectively, as the “Parties.” Certain capitalized terms used in this Agreement are defined in Exhibit A.
SECOND AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • February 25th, 2026 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of January 1, 2026 (the “Amendment Effective Date”), by and between Mark A. Goldsmith. M.D., Ph.D. (“Executive”) and Revolution Medicines, Inc., a Delaware corporation (“RevMed”).
REVOLUTION MEDICINES, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of April 17, 2026 0.50% Convertible Senior Notes due 2033First Supplemental Indenture • April 17th, 2026 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
This Supplemental Indenture (as defined below) is being executed and delivered pursuant to Sections 2.2 and 9.1(i) of the Base Indenture to establish the terms, and provide for the issuance, of a new series of Securities (as defined in the Base Indenture) constituting the Company’s 0.50% Convertible Senior Notes due 2033 (the “Notes”).
APPOINTMENT, ASSIGNMENT AND ASSUMPTION AGREEMENTAppointment, Assignment and Assumption Agreement • November 15th, 2023 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
THIS APPOINTMENT, ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is entered into and effective as of November 9, 2023 by and among EQRx, Inc., a Delaware corporation (the “Company”), Revolution Medicines, Inc. (“Parent”), Continental Stock Transfer & Trust Company, a New York corporation (“Continental”) and Equiniti Trust Company, LLC, a New York limited liability trust company (“Equiniti”).
FIFTH AMENDMENT TO LEASELease • November 6th, 2023 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
This FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) is made as of August 3, 2023 (the “Fifth Amendment Effective Date”), by and between HCP LS Redwood City, LLC, a Delaware limited partnership (“Landlord”) and Revolution Medicines, Inc., a Delaware corporation (“Tenant”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Revenue Participation Right Purchase and Sale Agreement By and Between...Purchase and Sale Agreement • August 6th, 2025 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • New York
This REVENUE PARTICIPATION RIGHT purchase and sale AGREEMENT (this “Agreement”), dated as of June 23, 2025 (the “Effective Date”), is made and entered into by and between Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”), and Revolution Medicines, Inc., a Delaware corporation (the “Seller”).
SUBLEASE AGREEMENTSublease Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Sublease Agreement (this “Sublease”) is dated as of February 4, 2019, for reference purposes only, by and between Revolution Medicines, Inc., a Delaware corporation (“Sublandlord”), as successor to Warp Drive Bio, LLC, a Delaware limited liability company, with Sublandlord having an address of 700 Saginaw Drive, Redwood City, CA 94063, Attn: General Counsel, (email: Legal@revolutionmedicines.com), and Casma Therapeutics, Inc., a Delaware corporation, (“Subtenant”), having an address at 29 Newbury Street, Boston, Massachusetts 02116 prior to the Commencement Date and at the Premises on and after the Commencement Date. This Sublease shall be effective as of the date set forth in Section 2, below.
FIRST AMENDMENT TO LEASELease Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
This First Amendment to Lease (the “First Amendment”) is made as of May 18, 2017, by and between ARE-TECH SQUARE, LLC, a Delaware limited liability company (“Landlord”), and WARP DRIVE BIO, INC., a Delaware corporation (“Tenant”), formerly known as WARP DRIVE BIO, LLC, a Delaware limited liability company.
FOURTH AMENDMENT TO LEASELease • May 8th, 2023 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
This FOURTH AMENDMENT TO LEASE ("Fourth Amendment") is made and entered into as of March 24, 2023 (the “Effective Date”), by and between HCP LS REDWOOD CITY, LLC, a Delaware limited partnership ("Landlord"), and REVOLUTION MEDICINES, INC., a Delaware corporation ("Tenant").
FIRST AMENDMENT TO LEASELease • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of September 16, 2016, by and between HCP LS REDWOOD CITY, LLC, a Delaware limited partnership (“Landlord”), and REVOLUTION MEDICINES, INC., a Delaware corporation (“Tenant”).